These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 12090463

  • 1. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity.
    Ganea D, Delgado M.
    Crit Rev Oral Biol Med; 2002; 13(3):229-37. PubMed ID: 12090463
    [Abstract] [Full Text] [Related]

  • 2. Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP.
    Ganea D, Delgado M.
    Arch Immunol Ther Exp (Warsz); 2001; 49(2):101-10. PubMed ID: 11348014
    [Abstract] [Full Text] [Related]

  • 3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
    Delgado M, Ganea D.
    J Immunol; 2001 Jan 15; 166(2):1028-40. PubMed ID: 11145682
    [Abstract] [Full Text] [Related]

  • 4. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression.
    Delgado M, Leceta J, Gomariz RP, Ganea D.
    J Immunol; 1999 Oct 01; 163(7):3629-35. PubMed ID: 10490956
    [Abstract] [Full Text] [Related]

  • 5. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression.
    Delgado M, Ganea D.
    J Immunol; 2000 Feb 01; 164(3):1200-10. PubMed ID: 10640731
    [Abstract] [Full Text] [Related]

  • 6. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
    Delgado M, Jonakait GM, Ganea D.
    Glia; 2002 Aug 01; 39(2):148-61. PubMed ID: 12112366
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
    Delgado M, Ganea D.
    J Immunol; 2000 Jul 01; 165(1):114-23. PubMed ID: 10861043
    [Abstract] [Full Text] [Related]

  • 11. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
    Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D.
    J Immunol; 1999 Apr 15; 162(8):4685-96. PubMed ID: 10202009
    [Abstract] [Full Text] [Related]

  • 12. VIP and PACAP enhance the in vivo generation of memory TH2 cells by inhibiting peripheral deletion of antigen-specific effectors.
    Delgado M, Ganea D.
    Arch Physiol Biochem; 2001 Oct 15; 109(4):372-6. PubMed ID: 11935376
    [Abstract] [Full Text] [Related]

  • 13. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity.
    Ganea D, Rodriguez R, Delgado M.
    Cell Mol Biol (Noisy-le-grand); 2003 Mar 15; 49(2):127-42. PubMed ID: 12887096
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo.
    Delgado M, Ganea D.
    J Immunol; 2001 Jul 15; 167(2):966-75. PubMed ID: 11441105
    [Abstract] [Full Text] [Related]

  • 15. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator.
    Gonzalez-Rey E, Varela N, Chorny A, Delgado M.
    Curr Pharm Des; 2007 Jul 15; 13(11):1113-39. PubMed ID: 17430175
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
    Delgado M, Ganea D.
    J Immunol; 2000 Sep 15; 165(6):3051-7. PubMed ID: 10975815
    [Abstract] [Full Text] [Related]

  • 17. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D.
    J Immunol; 1999 Feb 01; 162(3):1707-16. PubMed ID: 9973433
    [Abstract] [Full Text] [Related]

  • 18. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression.
    Delgado M, Sun W, Leceta J, Ganea D.
    J Immunol; 1999 Oct 15; 163(8):4213-23. PubMed ID: 10510358
    [Abstract] [Full Text] [Related]

  • 19. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP.
    Leceta J, Gomariz RP, Martinez C, Abad C, Ganea D, Delgado M.
    Ann N Y Acad Sci; 2000 Oct 15; 921():92-102. PubMed ID: 11193883
    [Abstract] [Full Text] [Related]

  • 20. VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells.
    Delgado M, Gonzalez-Rey E, Ganea D.
    FASEB J; 2004 Sep 15; 18(12):1453-5. PubMed ID: 15231725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.